MedTrace Logo

French National Registry of Children Born Small for Gestational Age Treated With Somatropin

NCT01578135 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 291

Last updated 2022-10-20

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of the study is to describe the patient population and therapeutic practices (study phase I), assess efficacy on growth and adult height and assess tolerance of somatropin (Norditropin® SimpleXx®) (study phase II)

Conditions

  • Growth Disorder
  • Small for Gestational Age

Interventions

DRUG

somatropin

Patients are to fill in a questionnaire at inclusion in registry

DRUG

somatropin

Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-18
Primary Completion
2018-10-09
Completion
2018-10-09
FDA Drug
Yes

Countries

  • France

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01578135 on ClinicalTrials.gov